[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurological-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurological-diseases":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100628032",false,"NCT07456358","Autoimmune Neurological Diseases and Those Secondary to Immunotherapy: Study of Immunological Mechanisms and Research Into Targets of Immune Attack","Maladies Neurologiques Auto-immunes et Secondaires à l'immunothérapie : étude Des mécanismes Immunologiques et Recherche Des Cibles de l'Attaque Immune","DINAMIC","Inclusion Criteria:\n\n* Adult patient (aged ≥ 18 years)\n* Affiliated with a social security scheme\n* Express consent to participate in the study\n* Indication for lumbar puncture And\n* Patients with cancer, undergoing treatment with ICIs, presenting neurological symptoms after starting treatment with ICIs. These symptoms must have appeared no more than 3 months after the last administration of ICIs.\n\nOr\n\n* Patients with an autoimmune disease of the central nervous system (diagnosis made by teams 1, 2 and 3) according to internationally recognised criteria, with no history of active cancer in the last 3 years and no other autoimmune disease Or\n* Patients with normal pressure hydrocephalus (NPH) or idiopathic intracranial hypertension (diagnosed based on imaging (brain MRI) and clinical findings), with no history of active cancer in the last 3 years and no active autoimmune disease\n\nExclusion Criteria:\n\n* Contraindication or refusal to perform a lumbar puncture\n* Sample not suitable for research (volume of CSF collected for treatment \\>5 mL)\n* Corticosteroid therapy or other immunomodulatory treatment in progress (discontinued less than 15 days prior to inclusion)\n* Pregnant or breastfeeding women\n* Not affiliated with the social security system, patients under French State Medical Aid for undocumented migrants\n* Patients under guardianship or curatorship, under judicial protection measures, or deprived of their liberty by judicial or administrative decision",true,"ALL","18 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"NA","The pathophysiology of neurological toxicities secondary to immune checkpoint inhibitors (ICIs) is unknown. Various mechanisms have been proposed: activation of cytotoxic CD8 T cells, autoantibodies via activation of B cells and CD4 cells, non-specific inflammation through the production of pro-inflammatory cytokines, and complement activation.\n\nThe aim of this research is to characterise the pathophysiological mechanisms of neurotoxicities in cancer patients treated with ICIs.",[27,28],"Neurological Diseases","Auto Immune Disease",[30,31,32,33],"Autoimmune neurological diseases","Immunotherapy","Neurotoxocities","Immune checkpoint inhibitors","NOT_YET_RECRUITING","2026-03-04",{"date":37,"type":38},"2026-03-06","ACTUAL",{"date":40,"type":21},"2026-03-01",{"date":42,"type":21},"2030-11-01",{"name":44,"class":45},"Assistance Publique - Hôpitaux de Paris","OTHER",""]